⚠ Scores are AI-generated estimates for informational purposes only — not investment advice. Data may be inaccurate or outdated. Do not make financial decisions based on this site. Full legal disclaimer →
⚠ Scores are AI-generated estimates for informational purposes only — not investment advice. Data may be inaccurate or outdated. Do not make financial decisions based on this site. Full legal disclaimer →
AI Exposure Analysis
Healthcare · Small Cap · Disruption threat: LOW
Tempus AI is a clinical AI company whose core business is built on applying machine learning to multimodal health data for oncology, cardiology, and other disease areas, making AI inseparable from its revenue model and product suite. The 10-K reaffirms deep AI integration across diagnostics, drug discovery partnerships, and data licensing, with continued investment in proprietary models and genomic-AI pipelines supporting a strong near-term growth outlook.
Tempus AI (TEM) is a clinical-stage AI company operating at the intersection of genomics, oncology, and machine learning. Its business is structurally inseparable from artificial intelligence, deploying AI-powered genomic and molecular diagnostics, a multimodal clinical data platform serving biopharma R&D, and algorithmic cardiology tools including ECG analysis. With an overall AI score of 78/100, Tempus represents one of the more deeply AI-native names in the small-cap healthcare space. The score is anchored by strong Product AI Integration at 88/100 and R&D AI Investment at 82/100, reflecting the company's commitment to proprietary model development and genomic-AI pipeline expansion. Internal AI Use (75/100) and AI Infrastructure (76/100) are solid, while Revenue from AI (72/100) indicates meaningful but still-maturing monetization of its data licensing and algorithmic insights business. The LOW disruption threat rating is notable. For Tempus, AI is not a threat to its model but the foundation of it. The company is positioned as a disruptor rather than a disruption target, with established biopharma partnerships and health system licensing relationships providing durable revenue visibility. The key risk is execution at scale. Converting a differentiated data and AI platform into consistent revenue growth, particularly in a capital-intensive small-cap structure, remains the central investor question heading into 2026.
Full interactive analysis at RankVis.io